Radioactive Iodine Dosimetry for Thyroid Cancer

Recruiting in Palo Alto (17 mi)

Overseen by Ravinder Grewal, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

One of the most effective treatments for metastases from thyroid cancer is a form of radioactive iodine known as 131-I. For more than 50 years, 131-I has been used to find and destroy thyroid cancer cells that have spread to other parts of the body. In many cases this treatment destroys the metastatic cells. However, in some patients it does not appear to work completely. This study is designed to use a slightly different form of radioactive iodine (called 124-I) which can precisely predict the amount of radiation that each metastatic lesion will receive. 124-I was developed at Memorial Sloan-Kettering in the 1950s and has been used here and at many other medical centers around the world for diagnostic studies. It has been found to be very safe and effective at finding metastatic lesions. The high resolution of newer PET scanners now allows us to carefully determine how much radiation each metastatic lesion will receive. If 124-I can accurately predict which patients will not respond to 131-I treatments we can then avoid exposing those patients to unnecessary radiation. For the rest of the patients we can custom tailor the 131-I dose to destroy the metastatic lesions.

Research Team

Ravinder Grewal, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for adults with thyroid cancer who've had their thyroid removed and previous treatment to eliminate remaining thyroid tissue. They must have metastases that absorb radioiodine, measurable disease documented in the last six months, and be planning further radioiodine therapy if needed. It's not for those under 18, pregnant, treated with radioiodine in the past nine months, or without metastases.

Inclusion Criteria

You have a documented measurable disease from an ultrasound, MRI, or CT scan within the past six months.

I have thyroid cancer with metastases that respond to radioiodine and am scheduled for a specific diagnostic test at MSKCC.

I am considering 131-I treatment for my thyroid cancer metastases.

Exclusion Criteria

My thyroid cancer has spread and does not respond to radioiodine treatment.

You are currently receiving treatment for another type of cancer.

I plan to stop taking thyroid hormone before my dosimetry test.

Treatment Details

Interventions

• 124 I-iodine (124-I) (Radioactive Iodine)
• 131 I-iodine (131-I) (Radioactive Iodine)

Trial Overview The study tests a radioactive iodine form called 124-I to predict radiation doses received by each cancer spread (metastatic lesion) using PET scans. This could help decide if patients will benefit from another type of radioactive iodine treatment (131-I), avoiding unnecessary exposure for non-responders.

Participant Groups

Group I: 1 Experimental Treatment 1 Intervention

131 I-iodine (131-I), 124 I-iodine (124-I)

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+

Lisa M. DeAngelis

Memorial Sloan Kettering Cancer Center

Chief Medical Officer since 2021

MD from Columbia University

Selwyn M. Vickers

Memorial Sloan Kettering Cancer Center

Chief Executive Officer since 2022

MD from Johns Hopkins University

Gustave Roussy, Cancer Campus, Grand Paris

Collaborator

Trials

270

Recruited

267,000+

Prof. Fabrice André

Gustave Roussy, Cancer Campus, Grand Paris

Chief Medical Officer since 2020

MD, specialization in breast cancer

Prof. Fabrice Barlesi

Gustave Roussy, Cancer Campus, Grand Paris

Chief Executive Officer

MD, specialization in oncology